ETF Holdings Breakdown of AMRX

Stock Name	Amneal Pharmaceuticals, Inc. Class A Common Stock
Ticker	AMRX(USD) NYSE
TYPE	Common Stock
Country	USA
ISIN	US03168L1052
LEI	549300VV176ZO5WQHZ61

AMRX institutional holdings

The following institutional investment holdings of AMRX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-01 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 83,989 USD 871,806 3.6%

2025-10-01 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 13,766 USD 142,891

2025-10-01 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 179,144 USD 1,859,515

2025-10-01 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 179,144 USD 1,859,515

2025-10-01 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,250 USD 12,975 3.6%

Total = 457,293 USD 4,746,702
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-01	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	83,989	USD 871,806 3.6%
2025-10-01	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	13,766	USD 142,891
2025-10-01	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	179,144	USD 1,859,515
2025-10-01	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	179,144	USD 1,859,515
2025-10-01	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,250	USD 12,975 3.6%
Total =	457,293	USD 4,746,702

News associated with AMRX

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) Given New $14.00 Price Target at JPMorgan Chase & Co.: AMNEAL PHARMACEUTICALS (NASDAQ:AMRX – Get Free Report) had its price target upped by JPMorgan Chase & Co. from $12.00 to $14.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 45.68% […] - 2025-09-18 02:24:44
AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) EVP Nikita Shah Sells 114,492 Shares of Stock: AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Get Free Report) EVP Nikita Shah sold 114,492 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $9.66, for a total transaction of $1,105,992.72. Following the completion of the transaction, the executive vice president directly owned 152,743 shares of […] - 2025-08-26 05:24:51
Andrew Boyer Sells 279,244 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) EVP Andrew Boyer sold 279,244 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the transaction, the executive vice president owned 152,426 shares in the […] - 2025-08-25 05:07:01
3,685 Shares in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) Acquired by Headlands Technologies LLC: Headlands Technologies LLC purchased a new position in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,685 shares of the company’s stock, valued at approximately $31,000. Other hedge funds have also recently added […] - 2025-08-14 04:56:57
Zurcher Kantonalbank Zurich Cantonalbank Buys 13,464 Shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX): Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Free Report) by 30.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,276 shares of the company’s stock after buying an additional 13,464 shares during the quarter. […] - 2025-08-08 04:56:48
Brokerages Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $11.60: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus rating of “Buy” by the five brokerages that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued ratings on the stock […] - 2025-07-29 02:48:58
Jennison Associates LLC Purchases New Position in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX): Jennison Associates LLC purchased a new stake in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX – Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 71,426 shares of the company’s stock, valued at approximately $599,000. A number of other institutional investors and hedge funds have […] - 2025-07-23 06:20:55
Massachusetts Financial Services Co. MA Has $1.40 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Massachusetts Financial Services Co. MA reduced its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 2.2% during the 1st quarter, HoldingsChannel.com reports. The firm owned 167,168 shares of the company’s stock after selling 3,810 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Amneal Pharmaceuticals were worth $1,401,000 at […] - 2025-07-21 05:52:49
Janney Montgomery Scott LLC Purchases 4,100 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Janney Montgomery Scott LLC increased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 26.9% in the 1st quarter, Holdings Channel reports. The fund owned 19,350 shares of the company’s stock after buying an additional 4,100 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Amneal Pharmaceuticals were worth $162,000 as of […] - 2025-07-07 04:20:50
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $11.60 Average Price Target from Analysts: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus recommendation of “Buy” by the five brokerages that are currently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock […] - 2025-07-04 02:00:54
Assenagon Asset Management S.A. Has $6.87 Million Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Assenagon Asset Management S.A. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 7.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 819,736 shares of the company’s stock after purchasing an additional 59,267 shares during the period. Assenagon Asset Management S.A. […] - 2025-06-15 05:43:09
California State Teachers Retirement System Acquires 12,282 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): California State Teachers Retirement System grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 10.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,713 shares of the company’s stock after purchasing an additional 12,282 shares during the period. […] - 2025-06-11 05:36:45
Two Sigma Advisers LP Has $347,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Two Sigma Advisers LP lessened its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 42.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 43,849 shares of the company’s stock after selling 32,400 shares during the quarter. Two Sigma Advisers LP’s holdings in […] - 2025-06-06 05:09:03
Squarepoint Ops LLC Increases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Squarepoint Ops LLC grew its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 540.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 124,744 shares of the company’s stock after purchasing an additional 105,268 shares during the period. Squarepoint Ops LLC’s holdings in Amneal Pharmaceuticals were worth $988,000 as of its most recent […] - 2025-06-01 05:31:01
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 2,911 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,460 shares of the company’s stock after buying an additional […] - 2025-05-28 04:50:51
Northern Trust Corp Raises Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Northern Trust Corp increased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 9.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,777,283 shares of the company’s stock after acquiring an additional 156,699 shares during the quarter. Northern Trust Corp’s holdings in Amneal Pharmaceuticals were worth $14,076,000 at the end of […] - 2025-05-16 04:23:00
Amneal Pharmaceuticals (NASDAQ:AMRX) Downgraded by StockNews.com to “Buy”: StockNews.com lowered shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday morning. A number of other analysts also recently issued reports on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and […] - 2025-05-14 04:58:47
Price T Rowe Associates Inc. MD Raises Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Price T Rowe Associates Inc. MD boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 11.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 97,250 shares of the company’s stock after buying an additional 9,704 shares during the quarter. […] - 2025-05-12 05:18:52
Voya Investment Management LLC Has $384,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Voya Investment Management LLC cut its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,488 shares of the company’s stock after selling 3,442 shares during the period. Voya […] - 2025-05-11 06:06:55
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Upgraded by StockNews.com: Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Monday. A number of other equities analysts have also recently weighed in on the stock. Barclays upped their price target on shares of Amneal Pharmaceuticals from $10.00 […] - 2025-05-07 03:06:47
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Dimensional Fund Advisors LP: Dimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 5.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,991,702 shares of the company’s stock after acquiring an additional 278,653 shares during the quarter. […] - 2025-05-05 05:18:54
Raymond James Financial Inc. Invests $2.95 Million in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Raymond James Financial Inc. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 371,996 shares of the company’s stock, valued at approximately $2,946,000. Several other institutional investors also recently added to or reduced […] - 2025-04-29 05:05:11
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.80 Consensus PT from Analysts: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has earned a consensus recommendation of “Buy” from the five analysts that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last […] - 2025-04-22 02:20:56
Wellington Management Group LLP Sells 8,577 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Wellington Management Group LLP trimmed its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 10.4% in the fourth quarter, HoldingsChannel reports. The firm owned 74,019 shares of the company’s stock after selling 8,577 shares during the quarter. Wellington Management Group LLP’s holdings in Amneal Pharmaceuticals were worth $586,000 as of its […] - 2025-04-15 05:32:51
Federated Hermes Inc. Purchases 5,849 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Federated Hermes Inc. lifted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 271,834 shares of the company’s stock after buying an additional 5,849 shares during the period. […] - 2025-04-14 05:15:03
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Arrowstreet Capital Limited Partnership: Arrowstreet Capital Limited Partnership reduced its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 25.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,541,058 shares of the company’s stock after selling 527,921 shares during the […] - 2025-04-06 05:27:00
Swiss National Bank Acquires 31,900 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Swiss National Bank lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 13.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 274,000 shares of the company’s stock after purchasing an additional 31,900 shares during the quarter. Swiss National Bank’s […] - 2025-03-28 05:54:50
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Principal Financial Group Inc.: Principal Financial Group Inc. grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 9.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 96,835 shares of the company’s stock after purchasing an additional 8,213 shares during the quarter. Principal Financial Group Inc.’s holdings in Amneal Pharmaceuticals were worth $767,000 as […] - 2025-03-07 06:21:06
Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $10.60: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus recommendation of “Buy” by the five research firms that are currently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the […] - 2025-03-05 04:55:12
Rhumbline Advisers Acquires 7,875 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX): Rhumbline Advisers boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 3.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 232,264 shares of the company’s stock after acquiring an additional 7,875 shares during the period. Rhumbline Advisers’ holdings in Amneal Pharmaceuticals were worth $1,840,000 as of its most recent SEC filing. […] - 2025-03-04 06:12:48

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.